Patterns and gaps in guideline-directed statin use for atherosclerotic cardiovascular disease by race and ethnicity by Ashish Sarraju, Xiaowei Yan, Qiwen Huang, Ramzi Dudum, Latha Palaniappan, Fatima Rodriguez

“…Objective: There remain disparities by race and ethnicity in atherosclerotic cardiovascular disease (ASCVD). Statins reduce low-density lipoprotein cholesterol (LDL-c) and improve ASCVD outcomes. …”
Get full text

Thermal Effect on Heat Shock Protein 70 Family to Prevent Atherosclerotic Cardiovascular Disease by Masayo Nagai, Hidesuke Kaji

“…In recent years, the expression of HSP70 in skeletal muscle has attracted attention for its use as a prevention of atherosclerotic cardiovascular disease (ASCVD) and as a disease marker. …”
Get full text

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation by Minglu Ma, Minglu Ma, Chang Hou, Chang Hou, Jian Liu, Jian Liu

Subjects: Get full text

A medical record-linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular disease by Zi Ye, Fara S Kalloo, Iftikhar J Kullo

Get full text

Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor by Avital Nahmias, Priska Stahel, Changting Xiao, Gary F. Lewis

“…There is consistent, unequivocal and reproducible epidemiological evidence derived from diverse populations that various indices of glycemia (fasting plasma glucose, post-prandial or post oral glucose challenge plasma glucose, HbA1c) are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), even in the prediabetic state. …”
Get full text

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients by Anthony Matta, Anthony Matta, Anthony Matta, Jean Pierre Rabès, Jean Pierre Rabès, Dorota Taraszkiewicz, Didier Carrié, Jérôme Roncalli, Jean Ferrières, Jean Ferrières

“…BackgroundHeterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of a causative genetic variant to predict ASCVD in HFH patients undergoing treatment.Materials and methodsA retrospective cohort was conducted on 289 patients with possible, probable, and definite diagnosis of HFH according to Dutch Lipid Clinic Network Score and in whom DNA analyses were performed and mean LDL-c level was above 155 mg/dl. …”
Get full text

Association of Triglyceride Glucose-Derived Indices with Recurrent Events Following Atherosclerotic Cardiovascular Disease by Sha Li, Hui-Hui Liu, Yan Zhang, Meng Zhang, Hui-Wen Zhang, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Rui-Xia Xu, Qian Dong, Ke-Fei Dou, Jie Qian, Jian-Jun Li

“…Background : Triglyceride glucose (TyG) and TyG-body mass index (TyG-BMI) are reliable surrogate indices of insulin resistance and used for risk stratification and outcome prediction in patients with atherosclerotic cardiovascular disease (ASCVD). Here, we inserted estimated average glucose (eAG) into the TyG (TyAG) and TyG-BMI (TyAG-BMI) as derived parameters and explored their clinical significance in cardiovascular risk prediction. …”
Get full text

Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease by Jie Wang, Yong-Mei Liu, Jun Hu, Cong Chen

“…Atherosclerosis (AS) is the pathology of atherosclerotic cardiovascular diseases (ASCVD), characterized by persistent chronic inflammation in the vessel wall, in which monocytes/macrophages play a key role. …”
Get full text

Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease by Jarred Prudencio, Paige Cajudoy, Donald Waddell

“…The American Diabetes Association recommends that patients with type II diabetes and atherosclerotic cardiovascular disease be prescribed an SGLT-2 inhibitor or GLP-1 agonist for cardioprotective benefit. …”
Get full text

An updated review on the link between oral infections and atherosclerotic cardiovascular disease with focus on phenomics by Mariana Bezamat

“…Atherosclerotic cardiovascular diseases (ACVD) and oral infections such as periodontal disease, dental caries, and apical periodontitis are diseases that affect a great portion of the worldwide population. …”
Get full text

Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults by Tiffany Yuen, MD, FRCPC, G.B. John Mancini, MD, FRCPC, FACP, FACC, Robert A. Hegele, MD, FRCPC, Glen J. Pearson, PharmD, FCCS

“…A High level of Lp(a) has been demonstrated to be an independent, causal, and prevalent risk factor for atherosclerotic cardiovascular disease (ASCVD), as well as aortic valve disease, through mechanisms that promote atherogenesis, inflammation, and thrombosis. …”
Get full text

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease by Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED

“…Wolfe Street, Baltimore, MD, 21287, USA, Tel +1 410-502-6813, Email edonnell@jhmi.eduAbstract: Multiple lines of evidence confirm that the cumulative burden of low-density lipoprotein cholesterol (LDL-C) is causally related to the development of atherosclerotic cardiovascular disease (ASCVD). As such, lowering LDL-C is a central tenet in all ASCVD prevention guidelines, which recommend matching the intensity of LDL-C lowering with the absolute risk of the patient. …”
Get full text

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels by Pierandrea Vinci, Nicola Fiotti, Emiliano Panizon, Letizia Maria Tosoni, Carla Cerrato, Federica Pellicori, Alessia Pirulli, Nicola Altamura, Paolo Schincariol, Filippo Giorgio Di Girolamo, Filippo Giorgio Di Girolamo, Gianni Biolo

Subjects: Get full text

Gallic acid: a dietary metabolite’s therapeutic potential in the management of atherosclerotic cardiovascular disease by Xiao-Lan Zhao, Zhang-Jing Cao, Ke-Di Li, Fei Tang, Li-Yue Xu, Jing-Nan Zhang, Dong Liu, Cheng Peng, Hui Ao, Hui Ao

“…Atherosclerotic cardiovascular disease (ASCVD) causes significant morbidity and mortality globally. …”
Get full text

Risk-enhancing factors and social determinants of health in risk assessment for atherosclerotic cardiovascular disease. by Yiyi Zhang, Jaejin An, Mengying Xia, Hui Zhou, Yifei Sun, Joanie Chung, Mengnan Zhou, Soon Kyu Choi, Kerresa L Morrissette, Paul Muntner, Monika M Safford, Carmen R Isasi, Alka M Kanaya, Brandon K Bellows, Lisandro D Colantonio, Kristi Reynolds, Andrew E Moran

“…<h4>Background</h4>The Pooled Cohort Equations (PCEs) do not accurately estimate atherosclerotic cardiovascular disease (ASCVD) risk in certain populations. …”
Get full text

Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease by Teimur Kayani, Bachar Ahmad, Rachel S. Chang, Frank Qian, Melis Sahinoz, Muhammad Waqar Rehan, Antonio Giaimo, Erica S. Spatz, Jiun-Ruey Hu

Subjects: Get full text

Coarctation of the aorta and accelerated atherosclerosis: A contemporary review on the burden of atherosclerotic cardiovascular disease by Melissa G.Y. Lee, Phillip S. Naimo, Anoop N. Koshy, Edward Buratto, William M. Wilson, Leeanne E. Grigg, Subodh B. Joshi, Katherine M. English

Get full text

Management Standards of Polypharmacy in Type 2 Diabetes Combined with Atherosclerotic Cardiovascular Diseases in the Elderly by ZENG Senxiang, YANG Rui, DENG Xun, YANG Ruitao, YANG Xiaoyan

Subjects: “…diabetes mellitus, type 2|atherosclerotic cardiovascular disease|polypharmacy|rational administration of drug|management…”
Get full text

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare by A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyanny, E. L. Kordzaya, E. Yu. Vasilyeva

“…To evaluate the effectiveness of PCSK9-targeted therapy (inclisiran, alirocumab, and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and who did not achieve the target low-density lipoprotein cholesterol (LDL-C) level on basic therapy (statins in maximum tolerated doses and/or ezetimibe).Material and methods. …”
Get full text

Digital Health Solutions to Reduce the Burden of Atherosclerotic Cardiovascular Disease Proposed by the CARRIER Consortium by Bart Scheenstra, Anke Bruninx, Florian van Daalen, Nina Stahl, Elizabeth Latuapon, Maike Imkamp, Lianne Ippel, Sulaika Duijsings-Mahangi, Djura Smits, David Townend, Inigo Bermejo, Andre Dekker, Laura Hochstenbach, Marieke Spreeuwenberg, Jos Maessen, Arnoud van 't Hof, Bas Kietselaer

“… Digital health is a promising tool to support people with an elevated risk for atherosclerotic cardiovascular disease (ASCVD) and patients with an established disease to improve cardiovascular outcomes. …”
Get full text